Literature DB >> 24630485

Early post-operative endoscopic recurrence in Crohn's disease patients: data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort.

Ambrogio Orlando1, Filippo Mocciaro2, Sara Renna3, Daniela Scimeca4, Antonio Rispo5, Maria Lia Scribano6, Anna Testa5, Annalisa Aratari7, Fabrizio Bossa4, Rosy Tambasco8, Erika Angelucci9, Sara Onali10, Maria Cappello11, Walter Fries12, Renata D'Incà13, Matteo Martinato13, Fabiana Castiglione5, Claudio Papi7, Vito Annese14, Paolo Gionchetti8, Fernando Rizzello8, Piero Vernia9, Livia Biancone10, Anna Kohn6, Mario Cottone3.   

Abstract

INTRODUCTION: The incidence of endoscopic recurrence (ER) in Crohn's disease following curative resection is up to 75% at 1 year. Endoscopy is the most sensitive method to detect the earliest mucosal changes and the severe ER at 1 year seems to predict a clinical relapse.
METHODS: The aim of this prospective study was to evaluate the incidence of early ER 6 months after curative resection. Secondary outcome was to evaluate the role of 5-aminosalicylic acid (5-ASA) in the prevention of ER at 6 months. A total of 170 patients were included in the study. They were carried-out from the evaluation of the appearance of ER during a trial performed to assess the role of azathioprine vs. 5-ASA as early treatment of severe ER. All the patients started 5-ASA treatment 2 weeks after surgery.
RESULTS: Six months after surgery ER was observed in 105 patients (62%). The endoscopic score was reported as severe in 78.1% of them (82 out of 105). At univariable analysis only ileo-colonic disease influenced the final outcome associating to a lower risk of severe ER (p=0.04; OR 0.52, 95% CI 0.277-0.974).
CONCLUSION: In this prospective Italian multicenter IG-IBD study a great proportion of ER occur within 6 months from ileo-colonic resection, with a significant rate of severe ER. Furthermore this study confirms the marginal role of 5-ASA in the prevention of ER. This suggests that post-surgical endoscopic evaluation should be performed at 6 months instead of 1 year to allow an adequate early treatment.
Copyright © 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  5-Aminosalicylic acid; Crohn's disease; Endoscopic recurrence; Severe recurrence

Mesh:

Substances:

Year:  2014        PMID: 24630485     DOI: 10.1016/j.crohns.2014.02.010

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  15 in total

Review 1.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

2.  Intravenous Contrast-Enhanced Ultrasound for Assessing and Grading Postoperative Recurrence of Crohn's Disease.

Authors:  María Jesús Martínez; Tomás Ripollés; Jose María Paredes; Eduardo Moreno-Osset; Juan Manuel Pazos; Esther Blanc
Journal:  Dig Dis Sci       Date:  2019-01-02       Impact factor: 3.199

Review 3.  Relevance of fecal calprotectin and lactoferrin in the post-operative management of inflammatory bowel diseases.

Authors:  Roberta Caccaro; Imerio Angriman; Renata D'Incà
Journal:  World J Gastrointest Surg       Date:  2016-03-27

4.  Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis.

Authors:  Zipporah Iheozor-Ejiofor; Morris Gordon; Andrew Clegg; Suzanne C Freeman; Teuta Gjuladin-Hellon; John K MacDonald; Anthony K Akobeng
Journal:  Cochrane Database Syst Rev       Date:  2019-09-12

Review 5.  The Evolving Role of Thiopurines in Inflammatory Bowel Disease.

Authors:  Saurabh Kapur; Stephen B Hanauer
Journal:  Curr Treat Options Gastroenterol       Date:  2019-09

6.  Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease.

Authors:  Teuta Gjuladin-Hellon; Morris Gordon; Zipporah Iheozor-Ejiofor; Anthony K Akobeng
Journal:  Cochrane Database Syst Rev       Date:  2019-06-20

Review 7.  Endoscopic evaluation of surgically altered bowel in patients with inflammatory bowel diseases.

Authors:  Preetika Sinh; Bo Shen
Journal:  Inflamm Bowel Dis       Date:  2015-06       Impact factor: 5.325

8.  Structural robustness of the gut mucosal microbiota is associated with Crohn's disease remission after surgery.

Authors:  S Mondot; P Lepage; P Seksik; M Allez; X Tréton; Y Bouhnik; J F Colombel; M Leclerc; P Pochart; J Doré; P Marteau
Journal:  Gut       Date:  2015-12-01       Impact factor: 23.059

9.  Impaired granulocyte-macrophage colony-stimulating factor bioactivity accelerates surgical recurrence in ileal Crohn's disease.

Authors:  Grace Gathungu; Yuanhao Zhang; Xinyu Tian; Erin Bonkowski; Leahana Rowehl; Julia Krumsiek; Billy Nix; Claudia Chalk; Bruce Trapnell; Wei Zhu; Rodney Newberry; Lee Denson; Ellen Li
Journal:  World J Gastroenterol       Date:  2018-02-07       Impact factor: 5.742

Review 10.  The Evolving Role of Thiopurines in Inflammatory Bowel Disease.

Authors:  Saurabh Kapur; Stephen B Hanauer
Journal:  Curr Treat Options Gastroenterol       Date:  2019-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.